Zelin Feng
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Zelin Feng has a total of 33 co-authors. Here are the top co-authors by number of shared publications:
- Xiaocang Cao
Department of Gastroenterology and Hepatology, Tianjin Medical University General Hospital, Tianjin Medical University, Tianjin, China
3 shared publications - Hetong Zhang
Department of Gastroenterology and Hepatology Tianjin Medical University General Hospital Tianjin China
2 shared publications - Huizhen Li
Department of Gastroenterology and Hepatology Tianjin Medical University General Hospital Tianjin China
2 shared publications - Qinghua Yi
Department of Gastroenterology and Hepatology Tianjin Medical University General Hospital Tianjin China
2 shared publications - Qiuyue Tu
Department of Gastroenterology and Hepatology Tianjin Medical University General Hospital Tianjin China
2 shared publications - Xinyue Wei
Department of Gastroenterology and Hepatology Tianjin Medical University General Hospital Tianjin China
2 shared publications
Latest Publications
- Open Access
- 10 March 2026
- Published by Wiley in Microbial Biotechnology
- Vol. 19 (3) , e70323
Advance Microbiota Transplantation: A Novel Addition–Subtraction Paradigm for Optimising Faecal Microbiota Transplantation
Faecal microbiota transplantation (FMT) is highly effective for recurrent Clostridioides difficile infection but yields inconsistent benefits in chronic indications. As a crude whole‐microbiota transplant, FMT contains numerous undefined active components, complicating efforts to ensure treatment predictability and stability. Therefore, we propose Advance Microbiota Transplantation (AMT), a comprehensive, phase‐based hypothesis that employs an addition–subtraction strategy throughout the pre‐, peri‐ and post‐transplant stages. AMT comprises donor and recipient pre‐treatment, procedural optimisation and post‐transplant adjuvant interventions to mitigate donor variability, ecological resistance, procedural heterogeneity and unstable engraftment. Through a systematic synthesis of current evidence‐based FMT research, we explored how the addition–subtraction strategy can be operationalised to shape the AMT concept and define testable, phase‐specific levers, thereby providing a foundation for future clinical translation. In parallel, we appraised the reporting quality using the Preferred Reporting Items for Microbiotherapy (PRIM) and identified six persistently under‐reported items that limit the interpretability, comparability, and reproducibility of FMT research. This review aims to facilitate the integration of AMT into clinical practice.
- 10 March 2026
- Published by Wiley in Microbial Biotechnology
- Vol. 19 (3) , e70323
Open AccessAdvance Microbiota Transplantation: A Novel Addition–Subtraction Paradigm for Optimising Faecal Microbiota Transplantation
Faecal microbiota transplantation (FMT) is highly effective for recurrent Clostridioides difficile infection but yields inconsistent benefits in chronic indications. As a crude whole‐microbiota transplant, FMT contains numerous undefined active components, complicating efforts to ensure treatment predictability and stability. Therefore, we propose Advance Microbiota Transplantation (AMT), a comprehensive, phase‐based hypothesis that employs an addition–subtraction strategy throughout the pre‐, peri‐ and post‐transplant stages. AMT comprises donor and recipient pre‐treatment, procedural optimisation and post‐transplant adjuvant interventions to mitigate donor variability, ecological resistance, procedural heterogeneity and unstable engraftment. Through a systematic synthesis of current evidence‐based FMT research, we explored how the addition–subtraction strategy can be operationalised to shape the AMT concept and define testable, phase‐specific levers, thereby providing a foundation for future clinical translation. In parallel, we appraised the reporting quality using the Preferred Reporting Items for Microbiotherapy (PRIM) and identified six persistently under‐reported items that limit the interpretability, comparability, and reproducibility of FMT research. This review aims to facilitate the integration of AMT into clinical practice.
- Open Access
- 1 September 2025
- Published by IMR Press in International Journal for Vitamin and Nutrition Research
- Vol. 95 (4) , 37353
Inflammatory-Driven Vitamin A Transport Dysfunction in Ulcerative Colitis
Background: Retinol-binding protein 4 (RBP4) is a vitamin A transport protein synthesized in the liver and also plays a crucial role in inflammation and immune regulation. Low serum vitamin A levels have been observed in both pediatric and adult patients with ulcerative colitis (UC). The association between serum vitamin A levels and serum RBP4 levels, as well as the underlying mechanism involved inimpaired vitamin A transport during inflammation in UC patients, has yet to been investigated. Methods: A validation cohort comprising 103 UC patients and 22 controls was analyzed. Serum RBP4 levels were measured using anenzyme-linked immunosorbent assay (ELISA), and correlations with vitamin A levels and disease severity wereassessed. A dextran sulfate sodium (DSS)-induced colitis mouse model was used to valuatehepatic RBP4 expression and inflammatory changes. Primary hepatocytes from C57BL/6 mice were exposed to inflammatory cytokines to assess the impact of these cytokines on RBP4 expression. Results: Serum vitamin A (p < 0.001) and RBP4 levels (p < 0.001) were significantly lower in UC patients compared to controls, exhibiting a pronounced decreasing trend as disease severity increased (vitamin A: p < 0.001; RBP4: p < 0.001), while vitamin A levels increased after effective treatment (p < 0.001). Hepatic RBP4 expression was reduced in the DSS-induced colitis model and negatively correlated with TNF-α, IL-6, and IL-17. Conclusions: Serum RBP4 levels are decreased in UC patients and negatively correlate with disease severity, possibly due to proinflammatory cytokine-induced suppression which might contribute to inflammation-driven vitamin A transport dysfunction.
- 1 September 2025
- Published by IMR Press in International Journal for Vitamin and Nutrition Research
- Vol. 95 (4) , 37353
Open AccessInflammatory-Driven Vitamin A Transport Dysfunction in Ulcerative Colitis
Background: Retinol-binding protein 4 (RBP4) is a vitamin A transport protein synthesized in the liver and also plays a crucial role in inflammation and immune regulation. Low serum vitamin A levels have been observed in both pediatric and adult patients with ulcerative colitis (UC). The association between serum vitamin A levels and serum RBP4 levels, as well as the underlying mechanism involved inimpaired vitamin A transport during inflammation in UC patients, has yet to been investigated. Methods: A validation cohort comprising 103 UC patients and 22 controls was analyzed. Serum RBP4 levels were measured using anenzyme-linked immunosorbent assay (ELISA), and correlations with vitamin A levels and disease severity wereassessed. A dextran sulfate sodium (DSS)-induced colitis mouse model was used to valuatehepatic RBP4 expression and inflammatory changes. Primary hepatocytes from C57BL/6 mice were exposed to inflammatory cytokines to assess the impact of these cytokines on RBP4 expression. Results: Serum vitamin A (p < 0.001) and RBP4 levels (p < 0.001) were significantly lower in UC patients compared to controls, exhibiting a pronounced decreasing trend as disease severity increased (vitamin A: p < 0.001; RBP4: p < 0.001), while vitamin A levels increased after effective treatment (p < 0.001). Hepatic RBP4 expression was reduced in the DSS-induced colitis model and negatively correlated with TNF-α, IL-6, and IL-17. Conclusions: Serum RBP4 levels are decreased in UC patients and negatively correlate with disease severity, possibly due to proinflammatory cytokine-induced suppression which might contribute to inflammation-driven vitamin A transport dysfunction.
- Open Access
- 27 May 2024
- Published by Wiley in Bioengineering & Translational Medicine
- Vol. 9 (5) , e10682
Propionate‐producing engineered probiotics ameliorated murine ulcerative colitis by restoring anti‐inflammatory macrophage via the GPR43/HDAC1/IL‐10 axis
Inflammatory bowel disease (IBD) is a chronic and unspecific inflammatory disorder of the gastrointestinal tract, and current treatment options often fail to maintain long‐term remission. Studies have shown that propionate level is reduced in fecal samples from patients with IBD. Propionate can ameliorate IBD through intestinal epithelial cells and immune regulation, but its effects on the inflammatory microenvironment and macrophage differentiation have not been widely studied. To address this, we constructed an engineered propionate‐producing probiotic (EcNP3) to achieve sustained restoration of propionate levels in the gut and increase its bioavailability. DSS‐induced experimental intestinal inflammation model was used to evaluate the effect of EcNP3 on improving the intestinal mucosal barrier and increasing the proportion of anti‐inflammatory macrophages. It was found that EcNP3 exhibited a restorative effect on the depletion of peritoneal anti‐inflammatory macrophages (F4/80hiCD11bhi) and significantly improved the expression level of IL‐10. Simultaneously, the expression of IL‐1β, IL‐6, and CXCL1 was downregulated while inhibiting apoptosis of tissue‐resident macrophages ex vivo. Further investigation revealed that EcNP3 regulates IL‐10 expression through G protein‐coupled receptor 43 and histone deacetylase. Furthermore, EcNP3 significantly inhibited the protein expression of HDAC1 and promoted the histone acetylation level of cells. Finally, EcNP3 significantly improved DSS‐induced colitis in mice by increasing mucus production and reducing inflammatory infiltration. Our results suggest that the engineered live biotherapeutic product EcNP3 is a safe and potently efficacious treatment for IBD, which defines a novel strategy in IBD therapy through macrophage IL‐10 signaling.
- 27 May 2024
- Published by Wiley in Bioengineering & Translational Medicine
- Vol. 9 (5) , e10682
Open AccessPropionate‐producing engineered probiotics ameliorated murine ulcerative colitis by restoring anti‐inflammatory macrophage via the GPR43/HDAC1/IL‐10 axis
Inflammatory bowel disease (IBD) is a chronic and unspecific inflammatory disorder of the gastrointestinal tract, and current treatment options often fail to maintain long‐term remission. Studies have shown that propionate level is reduced in fecal samples from patients with IBD. Propionate can ameliorate IBD through intestinal epithelial cells and immune regulation, but its effects on the inflammatory microenvironment and macrophage differentiation have not been widely studied. To address this, we constructed an engineered propionate‐producing probiotic (EcNP3) to achieve sustained restoration of propionate levels in the gut and increase its bioavailability. DSS‐induced experimental intestinal inflammation model was used to evaluate the effect of EcNP3 on improving the intestinal mucosal barrier and increasing the proportion of anti‐inflammatory macrophages. It was found that EcNP3 exhibited a restorative effect on the depletion of peritoneal anti‐inflammatory macrophages (F4/80hiCD11bhi) and significantly improved the expression level of IL‐10. Simultaneously, the expression of IL‐1β, IL‐6, and CXCL1 was downregulated while inhibiting apoptosis of tissue‐resident macrophages ex vivo. Further investigation revealed that EcNP3 regulates IL‐10 expression through G protein‐coupled receptor 43 and histone deacetylase. Furthermore, EcNP3 significantly inhibited the protein expression of HDAC1 and promoted the histone acetylation level of cells. Finally, EcNP3 significantly improved DSS‐induced colitis in mice by increasing mucus production and reducing inflammatory infiltration. Our results suggest that the engineered live biotherapeutic product EcNP3 is a safe and potently efficacious treatment for IBD, which defines a novel strategy in IBD therapy through macrophage IL‐10 signaling.